Abbott DeFT Response™ technology allows physicians to customize rescue therapy to each patient’s unique cardiac physiology and changing condition.
DeFT Response technology preserved a 10 J safety margin for 100% of the Abbott patients.
17% of the fixed-tilt group of patients with competitive devices had compromised the 10 J safety margin.
Group A: Adjustable
Group B: Fixed-tilt
Boston Scientific, Medtronic, Biotronik
|14J||—||20 (59%)||—||24 (34%)|
|21J||7 (20%)||3 (9%)||17 (24%)||8 (11%)|
|25J||1 (3%)||3 (9%)||7 (10%)||3 (4%)|
|31J||0||0||6 (8%)||4 (6%)|
Method: Analysis of DFT levels for 105 patients implanted with a single coil lead between Aug 2007 and Aug 2010.
DFT Testing: VF induced by synchronized T-wave shock or direct current pulse. If initial shock failed, second shock delivered at highest energy within 10 J safety margin of device. If unsuccessful, a subcutaneous coil implanted and DFT test repeated. Note: the RV-coil was specifically programmed as an anode in all devices.
*Applies to single coil systems.
You are about to enter an Abbott country- or region-specific website.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions
Do you wish to continue and enter this website?